Caribou Biosciences
Caribou Biosciences: A global provider of medical therapies and bio-based products based in Berkeley, US.
Founded
2011Caribou Biosciences: A global provider of medical therapies and bio-based products based in Berkeley, US.
Founded in Berkeley, Caribou Biosciences is a clinical-stage biopharmaceutical company dedicated to developing transformative genome-edited allogeneic cell therapies for severe human diseases. Their core mission is to leverage advanced CRISPR genome-editing technology to create precise and effective medical treatments. Caribou's patented chRDNA (CRISPR hybrid RNA-DNA) technology enables complex genome editing with high specificity and integrity, facilitating the development of off-the-shelf cell therapies.
Notable figures associated with Caribou Biosciences include co-founder Jennifer Doudna, a Nobel laureate in Chemistry. The company has attracted significant investment from leading venture capital firms, bolstering its research and development efforts. Key achievements include advancing their proprietary genome-editing platform and progressing multiple therapeutic candidates into clinical trials. Caribou's innovative approach has positioned them as a leader in the field of genome editing, with the potential to revolutionize treatments for various genetic disorders and cancers.
Companies similar to Caribou Biosciences include Editas Medicine, Mammoth Biosciences, Intellia Therapeutics and Acrigen Biosciences.
Caribou Biosciences was founded in 2011.
Caribou Biosciences' headquarters is located in Berkeley, CA, US.
Caribou Biosciences' most recent funding round was for $125M (USD) in July 2023.
As of Jul 13, 2023, Caribou Biosciences has disclosed funding of $317.7M (USD). Undisclosed round amounts are excluded.
Caribou Biosciences has 137 employees as of Feb 6, 2024.
Acrigen Biosciences
acrigen.com
